<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749602</url>
  </required_header>
  <id_info>
    <org_study_id>KCRB-Hadassah-01</org_study_id>
    <nct_id>NCT04749602</nct_id>
  </id_info>
  <brief_title>Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.</brief_title>
  <official_title>A Phase II Trial of Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kidney Cancer Research Bureau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kidney Cancer Research Bureau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced cancers who have pleural effusion, especially those requiring pleural&#xD;
      evacuation, experienced poorer survival when treated with immunotherapy. The pleura also acts&#xD;
      as a natural barrier that can limit the penetration of immune checkpoint inhibitors. In this&#xD;
      multicenter phase 2 study, the preliminary efficacy and toxicity of intrapleural instillation&#xD;
      of the nivolumab in patients with immune-sensitive metastatic cancers will be accessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients ≥18 years old who have large volume of pleural effusion, required evacuation, and&#xD;
      received systemic therapy with a checkpoint inhibitor (monotherapy or combination with&#xD;
      another checkpoint inhibitor) for metastatic cancers (renal cell carcinoma (RCC) and&#xD;
      non-small cell lung cancer (NSCLC) will be eligible. Drainage followed by nivolumab (40 mg,&#xD;
      single intrapleural instillation) will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-month recurrence-free survival</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients who will be without signs of radiographic recurrence after 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of any grade adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of patients who will experience any grade adverse events (according to CTCAE criteria ver. 5.0) associated with intrapleural nivolumab use</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Renal Cell Cancer Metastatic</condition>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>Pleural Effusion, Malignant</condition>
  <arm_group>
    <arm_group_label>Intrapleural instillation of the nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>40 mg of the nivolumab will be used intrapleurally (once).</description>
    <arm_group_label>Intrapleural instillation of the nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years old&#xD;
&#xD;
          -  Large volume of pleural effusion (1 liter and more), required evacuation&#xD;
&#xD;
          -  Systemic therapy with a checkpoint inhibitor (monotherapy or combination with another&#xD;
             checkpoint inhibitor)&#xD;
&#xD;
          -  Metastatic cancers (renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Autoimmune disorders&#xD;
&#xD;
          -  Previous treatment for&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya Tsimafeyeu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kidney Cancer Research Bureau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilya Tsimafeyeu, M.D.</last_name>
    <phone>+79265646581</phone>
    <email>kidneycancer@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasia Bondarenko</last_name>
      <phone>+74999054690</phone>
      <email>kidneycancer@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidney Cancer Research Bureau</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilya Tsimafeyeu</last_name>
      <phone>+79265646581</phone>
      <email>kidneycancer@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicine 24/7 clinic</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vadim Gutorov</last_name>
      <phone>+7 (495) 162-82-10</phone>
      <email>reg@medica24.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medscan</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Shrainer</last_name>
      <phone>+7 (495) 126-96-07</phone>
      <email>kidneycancer@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yauza clinical hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladislav Kosyrev</last_name>
      <phone>+7 (495) 234-42-42</phone>
      <email>info@yamed.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 7, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Intrapleural irrigation</keyword>
  <keyword>Pleural carcinomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

